INTRODUCTION :- This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
MECHANISM OF ACTION :-
* It is a specific and selective alpha-2 adrenoceptor agonist.
* By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals.
* Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
PHARMACOKINETICS :-
* Protein binding :- 94%
* Volume of distribution :- 118 L
* Half life :- 2 hrs
* Route of administration :-:- Urine and 4% in feces.
SIDE EFFECTS :-
* Decreased blood pressure observed at lower concentrations
* Elevated blood pressure at higher concentrations.
* Rapid IV administration or bolus has been associated with slow heart rate (bradycardia)
* Low blood pressure (hypotension) due to peripheral α2-receptor stimulation.
DRUG-DRUG INTERACTIONS :-
* CERITINIB+ DEXMEDETOMIDINE= It may increase the bradycardic activities of Ceritinib.
* DULOXETINE+ DEXMEDETOMIDINE= It may increase the orthostatic hypotensive activities of Duloxetine.
* HEPTABARBITAL + DEXMEDETOMIDINE= It may increase the hypotensive activities of Dexmedetomidine.
THERAPEUTIC USES :-
* It is most often used in the intensive care setting for light to moderate sedation.
* It is used in veterinary medicine for its analgesic and sedative properties.
REFERENCE: Tripathi K.D, "Essentials of medical pharmacology" Edition- 7th, page no.-384
No comments:
Post a Comment